MOTS-c Research Profile

Interest in MOTS-c has grown mainly because of its connection with cellular metabolism, mitochondrial signalling and the body’s response to metabolic stress. It has also attracted attention in research into ageing, exercise and insulin sensitivity. That said, much of the excitement around MOTS-c is still ahead of the human evidence. A significant proportion of the research remains based on cells and animal models rather than controlled clinical studies in people.

What is MOTS-c?

MOTS-c belongs to a group known as mitochondrial-derived peptides (MDPs). These peptides are produced from short open reading frames in mitochondrial DNA. Humanin and several small humanin-like peptides are other examples from the same broader group.

MOTS-c was first described in 2015 and quickly became intriguing because it appeared to act as more than a simple by-product of mitochondrial activity. Research suggests that it can participate in communication between mitochondria and the rest of the cell, particularly when cells encounter metabolic stress.

One feature that makes MOTS-c especially interesting is its relationship with AMP-activated protein kinase (AMPK) and other pathways involved in maintaining energy balance. Experimental work has also suggested that, under certain forms of stress, MOTS-c can move into the cell nucleus and influence gene expression. The proposed role is essentially one of helping the cell adapt when its usual metabolic conditions change.

Why are researchers interested in it?

A lot of MOTS-c research comes back to metabolism.

Researchers have investigated the peptide in laboratory studies, focusing on glucose handling, insulin sensitivity, energy use, and adaptation to metabolic stress. Animal research has produced particularly interesting findings. For example, studies in mice have reported changes in insulin resistance, physical performance and skeletal-muscle metabolism following MOTS-c administration.

This has led to wider interest in whether MOTS-c could eventually have relevance to conditions associated with metabolic dysfunction.

There is also an ageing angle. Circulating MOTS-c appears to change with age, and researchers have investigated whether declining mitochondrial signalling could be linked to some of the metabolic changes seen during ageing. Reviews have discussed possible connections with diabetes, cardiovascular disease, osteoporosis and other age-associated conditions, although these proposed applications remain research questions rather than established treatments.

That distinction matters. A biological mechanism that looks promising in a mouse or cultured cell does not automatically translate into a useful or safe treatment for humans.

MOTS-c and exercise research

Exercise is another area where MOTS-c keeps appearing.

Researchers have found evidence that physical activity can affect circulating mitochondrial-derived peptides, including MOTS-c. One human study examined both endurance and resistance exercise and measured changes in MOTS-c in blood and skeletal muscle.

Other human research has looked at MOTS-c in different metabolic settings. For example, one study involving people with and without polycystic ovary syndrome found that lipid infusion increased circulating MOTS-c, while insulin affected that response. An eight-week exercise intervention, however, did not produce a significant change in circulating MOTS-c in the groups studied.

So the relationship between MOTS-c and exercise is not quite as simple as saying that exercise simply “raises MOTS-c”. Results can depend on the exercise protocol, metabolic state, population and how the peptide is measured.

A 2026 systematic review of mitochondrial-derived peptides and exercise reached a similar general conclusion: existing studies point towards an association between physical activity and changes in MDP levels, but the number of human studies remains limited and the findings vary between studies.

What does the research actually show?

There are some genuinely interesting findings, but they need to be kept in context.

Preclinical studies have suggested that MOTS-c may influence pathways involved in glucose metabolism, mitochondrial function, cellular stress responses and skeletal-muscle adaptation. Animal experiments have also reported effects on physical performance and metabolic health.

More recent laboratory research has continued to investigate possible roles in metabolic ageing. For example, in 2025, a study published results supporting the claim that MOTS-c is associated with cellular senescence and diabetic pathology in the pancreatic beta cell context, contributing to the volume of evidence on the substance’s nature, but being an experimental study conducted on cells and not an actual clinical trial that would verify human-level results.

Human research is currently much more limited.

Studies have measured naturally occurring MOTS-c in people and explored how levels respond to exercise, lipids and different health conditions. These studies are useful for understanding the biology of the peptide, but they are not equivalent to clinical trials demonstrating that administering MOTS-c to people is effective for treating a disease.

Safety and regulatory position

This is probably the area where the greatest caution is needed.

MOTS-c is sometimes discussed online alongside experimental peptide products and is marketed in some places for claims involving metabolism, weight management, exercise performance or other effects. Those claims should not be confused with established clinical evidence.

The US Food and Drug Administration’s 2026 assessment of MOTS-c-related bulk drug substances found a lack of human safety and effectiveness data for drug products containing MOTS-c. The FDA also highlighted unanswered questions around peptide characterisation, impurities and potential immunogenicity, particularly for injectable preparations. It stated that MOTS-c is not a component of an FDA-approved drug.

That does not mean the underlying science is uninteresting. It means the gap between laboratory research and properly evaluated human medicine is still substantial.

MOTS-c in current research

For researchers, MOTS-c is interesting partly because it challenges the older view of mitochondria as structures concerned mainly with energy production. The peptide appears to be involved in signalling between mitochondrial activity, cellular stress and metabolic regulation.

There is still plenty to investigate: how MOTS-c acts in different tissues, which receptors or molecular targets are involved, how its production is regulated, what happens to it in the circulation, and whether experimentally observed effects can be reproduced safely in humans.

For now, MOTS-c is best understood as an experimental mitochondrial-derived peptide with promising but incomplete research findings. Its potential links with metabolism, exercise and ageing make it an active area of scientific interest, but those potential applications should not be presented as established medical benefits.

The most useful way to follow MOTS-c research is therefore to separate three things: what has been demonstrated in laboratory models, what has actually been observed in human studies, and what remains a proposed therapeutic application. That distinction is particularly important with newer peptides, where commercial claims can move considerably faster than the clinical evidence.